<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089112</url>
  </required_header>
  <id_info>
    <org_study_id>HM-BAVI-101</org_study_id>
    <nct_id>NCT03089112</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501</brief_title>
  <official_title>A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interactions and the Safety Between HGP1607 and HGP1501 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic drug
      interactions and the Safety between HGP1607 and HGP1501 in Healthy Male Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of HGP1607</measure>
    <time_frame>16, -12, -8, 0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96,120h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of HGP1607</measure>
    <time_frame>16, -12, -8, 0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96,120h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>baseline corrected AUClast of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>baseline corrected Cmax of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of HGP1607</measure>
    <time_frame>16, -12, -8, 0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of HGP1607</measure>
    <time_frame>16, -12, -8, 0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of HGP1607</measure>
    <time_frame>16, -12, -8, 0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baseline corrected AUCinf of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baseline corrected Tmax of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baseline corrected T1/2 of HGP1501</measure>
    <time_frame>0,1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96,120h</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Seguence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seguence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seguence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seguence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seguence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seguence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1607</intervention_name>
    <arm_group_label>Seguence 1</arm_group_label>
    <arm_group_label>Seguence 2</arm_group_label>
    <arm_group_label>Seguence 3</arm_group_label>
    <arm_group_label>Seguence 4</arm_group_label>
    <arm_group_label>Seguence 5</arm_group_label>
    <arm_group_label>Seguence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1501</intervention_name>
    <arm_group_label>Seguence 1</arm_group_label>
    <arm_group_label>Seguence 2</arm_group_label>
    <arm_group_label>Seguence 3</arm_group_label>
    <arm_group_label>Seguence 4</arm_group_label>
    <arm_group_label>Seguence 5</arm_group_label>
    <arm_group_label>Seguence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1607+HGP1501</intervention_name>
    <arm_group_label>Seguence 1</arm_group_label>
    <arm_group_label>Seguence 2</arm_group_label>
    <arm_group_label>Seguence 3</arm_group_label>
    <arm_group_label>Seguence 4</arm_group_label>
    <arm_group_label>Seguence 5</arm_group_label>
    <arm_group_label>Seguence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.age 19~40 years

          -  2.The result of BMI is not less than 19 kg/m2 , no more than 28 kg/m2

          -  3.Subjects who have ability to comprehend the objectives, contents of study and
             property of study drug before participating in trial and have willingness to sign of
             informed consent in writing

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in digestive system, neuropsychiatric system, endocrine system,
             liver, cardiovascular system

          2. Subjects who judged ineligible by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HyunJi Park</last_name>
    <phone>02-410-0497</phone>
    <email>hyunssun1@hanmi.co.kr</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

